SCOTTSDALE, Ariz., Feb. 26 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for Rheumatoid Arthritis (RA) therapies.
In this report, entitled MedPredict Thought Leader Insight & Analysis:
Rheumatoid Arthritis Q1 2008, MedPredict's global Thought Leader Panel
debates tough questions facing drug developers:
-- How should rheumatologists sequence/stack biologicals? What will
challenge the anti-TNF paradigm? T-cell? B-cell? Mesenchymal cell?
-- How big of a benefit will oral dosing provide in this patient
population? Syk? Jak? p38? CCR? Will orals move RA treatment into
-- What do they hear from Pharma? What will Wyeth do when they return to
Amgen the rights to etanercept? How strong is AstraZeneca's
commitment to arthritis?
-- Why is it so hard to treat gout?
"There continue to be significant unmet needs in this market," says MedPredict President Jeffrey D. Berk. "According to our Panelists, only half of RA patients achieve remission on their first biological therapy and these remissions aren't durable. Even with completely new options many patients are left under-satisfied and demanding better results from their physicians. This report sheds light on these unmet needs and reveals Panelists' views of the most promising candidates."
Drugs/Companies mentioned in this report: allopurinol; febuxostat
(Teijin/Ipsen/TAP); Puricase (pegloticase; Savient); Remicade (infliximab;
Centocor/Schering-Plough/Essex), Enbrel (etanercept; Wyeth/Amgen); Humira
(adalimumab; Abbott), Orencia (abatacept; Bristol-Myers Squibb); MabThera
(rituximab; Roche/Biogen/Genentech); methotrexate (generic); denosumab
(Amgen); golimumab (Centocor/Schering-Plough/Essex);
Copyright©2008 PR Newswire.
All rights reserved